Senseonics Holdings Inc (SENS) Sees Large Growth in Short Interest
Senseonics Holdings Inc (NYSEAMERICAN:SENS) was the target of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 4,635,391 shares, an increase of 17.5% from the January 12th total of 3,946,300 shares. Currently, 9.6% of the shares of the company are short sold. Based on an average daily volume of 667,199 shares, the short-interest ratio is currently 6.9 days.
Separately, Canaccord Genuity reissued a “buy” rating on shares of Senseonics in a research report on Wednesday, November 1st.
Shares of Senseonics (NYSEAMERICAN SENS) opened at $2.51 on Wednesday. Senseonics has a 1 year low of $1.26 and a 1 year high of $3.67. The company has a debt-to-equity ratio of 0.76, a quick ratio of 2.81 and a current ratio of 2.93. The stock has a market cap of $352.88 and a price-to-earnings ratio of -5.16.
Several hedge funds have recently modified their holdings of the company. Raymond James Financial Services Advisors Inc. grew its position in shares of Senseonics by 38.9% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 487,175 shares of the company’s stock valued at $1,296,000 after acquiring an additional 136,425 shares during the period. Goldman Sachs Group Inc. bought a new stake in shares of Senseonics during the 2nd quarter valued at $276,000. Susquehanna International Group LLP bought a new stake in shares of Senseonics during the 2nd quarter valued at $155,000. Citadel Advisors LLC bought a new stake in shares of Senseonics during the 3rd quarter valued at $194,000. Finally, Perceptive Advisors LLC bought a new stake in shares of Senseonics during the 3rd quarter valued at $160,000. 30.66% of the stock is owned by hedge funds and other institutional investors.
Senseonics Company Profile
Senseonics Holdings, Inc is a medical technology company. The Company focuses on the design, development and commercialization of glucose monitoring systems. The Company operates through glucose monitoring systems segment. It offers a continuous glucose monitoring (CGM) system, Eversense, which is designed an implantable CGM system designed to continually measure glucose levels in people with diabetes.
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.